Abstract | OBJECTIVE: DESIGN: Multicenter, placebo-controlled, double-masked, randomized trial. PARTICIPANTS: Twenty-two patients with AKC refractory to topical steroid treatment. INTERVENTION: Patients were randomly assigned (1:1) to treatment with topical 0.05% cyclosporin A eyedrops or a placebo ( artificial tears) for a period of 28 days, 6 times daily during the first 2 weeks and 4 times daily during the last 2 weeks. MAIN OUTCOME MEASURES: RESULTS: A composite score computed by summing the severity grade over all 5 symptoms and 6 signs of AKC for each patient indicated a greater improvement in the cyclosporin A group relative to the placebo at the end of the 4-week treatment period (P = 0.048 and P = 0.002, for symptoms and signs, respectively). No adverse effects of the treatment with cyclosporin A 0.05% eyedrops were observed. CONCLUSIONS: Topical cyclosporin A 0.05% seems to be safe and have some effect in alleviating signs and symptoms of severe AKC refractory to topical steroid treatment.
|
Authors | Esen Karamursel Akpek, John K Dart, Stephanie Watson, William Christen, Dilek Dursun, Sonia Yoo, Terrence P O'Brien, Oliver D Schein, John D Gottsch |
Journal | Ophthalmology
(Ophthalmology)
Vol. 111
Issue 3
Pg. 476-82
(Mar 2004)
ISSN: 0161-6420 [Print] United States |
PMID | 15019322
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Glucocorticoids
- Immunosuppressive Agents
- Ophthalmic Solutions
- Cyclosporine
|
Topics |
- Administration, Topical
- Adult
- Aged
- Conjunctivitis, Allergic
(drug therapy)
- Cyclosporine
(administration & dosage, adverse effects)
- Double-Blind Method
- Drug Resistance
- Female
- Glucocorticoids
(therapeutic use)
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Ophthalmic Solutions
(administration & dosage)
- Safety
|